Quinolone derivatives as fibroblast growth factor inhibitors

Patent metadata

Field	Value
Publication number	US-9630963-B2
Application number	US-201414934885-A
Country	US
Kind code	B2
Filing date	May 7, 2014
Priority date	May 9, 2013
Publication date	Apr 25, 2017
Grant date	Apr 25, 2017

Abstract

Compounds that are Fibroblast Growth Factor Inhibitors (FGFR) and are therefore useful for the treatment of diseases treatable by inhibition of FGFR are disclosed. Also disclosed are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

First claim

What is claimed is:

1. A compound of Formula (I′):

or a pharmaceutically acceptable salt thereof; wherein:
Z is N;
Ar is phenyl optionally substituted with one, two, three, or four substituents independently selected from alkyl, cycloalkyl, hydroxy, alkoxy, halo, haloalkyl, alkyl sulfonyl, haloalkoxy, and cyano;
R 1 is hydrogen;
R 2 is hydrogen, alkyl, alkynyl, cycloalkylalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, heterocyclyl (wherein the heterocyclyl is optionally substituted with one or two substituents independently selected from alkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocyclyl), heterocyclylalkyl (wherein the heterocyclyl ring in heterocyclylalkyl is optionally substituted with one or two substituents independently selected from alkyl, hydroxy, hydroxyalkyl, aminoalkyl, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocyclyl), heteroaryl (where the heteroaryl is optionally substituted with one, two, or three substituents where two of the heteroaryl optional substituents are independently selected from alkyl, hydroxy, alkoxy, halo, haloalkyl, haloalkoxy, and cyano and one of the heteroaryl optional substituents is alkyl, cycloalkyl, hydroxy, alkoxy, halo, haloalkyl, haloalkoxy, cyano, hydroxyalkyl, alkoxyalkyl, aminoalkyl, optionally substituted aryl, optionally substituted heteroaryl or optionally substituted heterocyclyl), or heteroaralkyl where the heteroaryl ring in the heteroaralkyl is optionally substituted with one, two, or three substituents independently selected from halo, alkyl, hydroxy, alkoxy, and haloalkoxy;
alk is alkylene;
X is a group of formula (a) or (b):

wherein:
Ar 1 is phenylene, pyridinylene, thiazolylene, pyrazinylene or imidazolylene;

Ring B is piperidinyl, where the nitrogen atom of the piperidinyl ring is attached to Y;
R 3 is hydrogen, alkyl, hydroxy, alkoxy, halo, haloalkyl, haloalkoxy, or cyano;
R 4 is hydrogen, alkyl, cycloalkyl, hydroxy, alkoxy, halo, haloalkyl, haloalkoxy, or cyano;
R 5 and R 6 are independently hydrogen, alkyl, or halo;
Y is CO— or —SO 2 —;
R b is hydrogen or alkyl;
R c is hydrogen, alkyl, or substituted alkyl; and
R d is hydrogen or alkyl;

provided that (i) alk and —NR b —Y—CH═CR c R d are meta or para to each other and (ii) alk and —Y—CH═CR c R d are meta or para to each other.

2. The compound of claim 1 or a pharmaceutically acceptable salt thereof wherein the compound has the structure (Ib):

3. The compound of claim 1 or a pharmaceutically acceptable salt thereof where Ar is 2-chloro-3,5-dimethoxy-phenyl, 3,5-dimethoxyphenyl, 2-chlorophenyl, or 2,6-dichloro-3,5-dimethoxyphenyl.

4. The compound of claim 1 or a pharmaceutically acceptable salt thereof where R 2 is alkyl.

5. The compound of claim 1 and/or a pharmaceutically acceptable salt thereof where R 2 is aminoalkyl.

6. The compound of claim 1 or a pharmaceutically acceptable salt thereof where R 2 is methyl, ethyl, prop-2-yl, 2,2-dimethylprop-1-yl, 2-hydroxy-2-methylprop-1-yl, 2,3-dihydroxyprop-1-yl, 2-hydroxyethyl, 1,3-dihydroxyprop-2-yl, 3-hydroxy-2-methylprop-2-yl, 3-hydroxy-2,2-dimethylprop-1-yl, 1,3-dihydroxy-2-methylprop-2-yl, 1,3-dihydroxy-2-ethylprop-2-yl, dimethylaminoethyl, ethylaminoethyl, 3-dimethylaminopropyl, 3-ethylaminopropyl, 4-dimethylaminobutyl, 4-ethylaminobutyl, methyl, ethyl, propyl or butyl substituted with: morpholin-4-yl, 2,6-dimethylmorpholin-4-yl, piperazin-1-yl, 4-methylpiperazin-1-yl, 4-ethylpiperazin-1-yl, 4-acetylpiperazin-1-yl, 4-isopropylpiperazin-1-yl, 4-(2-hydroxy-2-methylprop-2-yl)piperazin-1-yl, piperidin-1-yl, 1-methylpiperidin-4-yl, 1,2-dioxothiomorpholin-4-yl, 4-oxetan-3-ylpiperazin-1-yl, 2,6-dimethylpiperazin-1-yl, 3,5-dimethylpiperazin-1-yl, 4-hydroxy-1-methylpiperidin-4-yl, 4,4-difluoropiperidin-1-yl, or 1,4-dimethylpiperidin-4-yl.

7. The compound of claim 1 or a pharmaceutically acceptable salt thereof where Ar 1 is phenylene where the alk and —NHYCH═CHR c group are meta or para to each other on the phenylene ring.

8. The compound of claim 1 and/or a pharmaceutically acceptable salt thereof where Ar 1 is pyridinylene and the nitrogen atom of the pyridinylene ring is position #1 and where (i) alk is attached to the C-2 or C-3 carbon of the pyridinylene ring and the —NHYCH═CHR c group is attached to the C-6 position of the pyridinylene ring or (ii) alk is attached to the C-4 carbon of the pyridinylene ring and the —NHYCH═CHR c group is at C-2 position of the pyridinylene ring.

9. The compound of claim 1 or a pharmaceutically acceptable salt thereof where Y is —CO—.

10. The compound of claim 1 or a pharmaceutically acceptable salt thereof where R c is hydrogen.

11. The compound of claim 1 or a pharmaceutically acceptable salt thereof where R c is —CH 2 NRR′, where R is hydrogen, alkyl, hydroxyalkyl, alkoxyalkyl, or heterocyclyl optionally substituted with one or two groups independently selected from alkyl, hydroxyl, alkoxy, or halo and R′ is hydrogen, alkyl, or cycloalkyl.

12. A compound selected from the group consisting of:
N-(4-(2-(6-(2-chlorophenyl)-2-((4-(diethylamino)butyl)amino)-7-oxopyrido[2,3-d]-pyrimidin-8(7H)-yl)ethyl)phenyl)prop-2-enamide;
8-(2-(1-acryloylpiperidin-3-yl)ethyl)-6-(2-chlorophenyl)-2-(4-(diethylamino)butylamino)pyrido[2,3-d]pyrimidin-7(8H)-one;
N-(3-(2-(6-(2-chlorophenyl)-2-((4-(diethylamino)butyl)amino)-7-oxopyrido[2,3-d]-pyrimidin-8(7H)-yl)ethyl)phenyl)acrylamide;
N-(4-(2-(6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)-7-oxopyrido[2,3-d]-pyrimidin-8(7H)-yl)ethyl)phenyl)acrylamide;
N-(4-(2-(6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-((4-(diethylamino)butyl)amino)-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)ethyl)phenyl)acrylamide;
N-(3-((6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-((4-(diethylamino)butyl)amino)-7-oxo-pyrido[2,3-d]pyrimidin-8(7H)-yl)methyl)phenyl)acrylamide;
N-(3-(2-(6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-((4-(diethylamino)butyl)amino)-7-oxo-pyrido[2,3-d]pyrimidin-8(7H)-yl)ethyl)phenyl)acrylamide;
N-(3-(2-(6-(3,5-dimethoxyphenyl)-2-(methylamino)-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)ethyl)phenyl)acrylamide;
N-(4-(2-(6-(3,5-dimethoxyphenyl)-2-(methylamino)-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)ethyl)phenyl)acrylamide;
N-(4-(2-(6-(3,5-dimethoxyphenyl)-2-(methylamino)-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)ethylpyridinyl-2-yl)acrylamide;
N-(6-(2-(6-(3,5-dimethoxyphenyl)-2-(methylamino)-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)ethylpyridinyl-2-yl)acrylamide;
N-(3-(2-(6-(2-chloro-3,5-dimethoxyphenyl)-2-(methylamino)-7-oxopyrido[2,3-d]-pyrimidin-8(7H)-yl)ethyl)phenyl)acrylamide;
N-(4-(2-(6-(2-chloro-3,5-dimethoxyphenyl)-2-(methylamino)-7-oxopyrido[2,3-d]-pyrimidin-8(7H)-yl)ethyl)phenyl)acrylamide;
N-(4-(2-(6-(2-chloro-3,5-dimethoxyphenyl)-2-(methylamino)-7-oxopyrido[2,3-d]-pyrimidin-8(7H)-yl)ethyl)pyridin-2-yl)acrylamide;
N-(6-(2-(6-(2-chloro-3,5-dimethoxyphenyl)-2-(methylamino)-7-oxopyrido[2,3-d]-pyrimidin-8(7H)-yl)ethylpyridin-2-yl)acrylamide;
N-(5-(2-(6-(2-chloro-3,5-dimethoxyphenyl)-2-(methylamino)-7-oxopyrido[2,3-d]-pyrimidin-8(7H)-yl)ethylpyridin-2-yl)acrylamide;
N-(4-(2-(6-(2-chloro-3,5-dimethoxyphenyl)-2-(methylamino)-7-oxopyrido[2,3-d]-pyrimidin-8(7H)-yl)ethyl)phenyl)-N-methylacrylamide;
N-(3-(2-(6-(2-chloro-3,5-dimeth

Assignees

• Principia Biopharma Inc

Inventors

• Brameld Kenneth Albert
• Verner Erik

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• C07D471/04 Primary

  Ortho-condensed systems · CPC title